'Right to try' seeks traction in US (Update)

March 13, 2018
Doctors and groups representing patients with rare diseases say the law would create false hope and would change nothing in reality

Faced with certain death, what do patients have to lose by trying experimental drugs that have not been approved for the market?

It could be a child with a rare form of muscular dystrophy. A young woman ravaged by colon cancer. Or a grandfather trapped in the slow decline of Lou Gehrig's disease.

Drugs that are already on the market—if they exist—no longer work for them. They want to take part in a clinical trial but can't, either because they are too sick, too young, too old or too far away.

It is this desperate population that lawmakers—both Democrat and Republican in 38 of the 50 US states—have been trying to help by adopting "right to try" laws for experimental treatments that may be given outside of clinical trials.

The cause is so popular that President Donald Trump and Vice President Mike Pence have put all their weight behind it.

The Senate has passed a measure on establishing a national "right to try" law, but the House of Representatives voted Tuesday not to move forward with its own version.

Republican leaders in the lower chamber said they would try again—and see the measure passed.

Doctors and groups representing patients with rare diseases, however, say a law would create false hope and would change nothing in reality.

Today, doctors can already ask pharmaceutical companies to give them an experimental drug for compassionate use, as long as it has passed the initial safety steps in clinical trials that show it is not toxic or life-threatening.

It's unclear how many drug companies comply, but the US Food and Drug Administration approves such requests in 99 percent of cases, usually in a matter of days.

Every year, about a thousand patients take advantage of this "expanded access" program offered by the FDA.

"People have been helped, yes, but it is unusual," Arthur Caplan, director of medical ethics at New York University's School of Medicine, told AFP.

"Most drugs fail in research," he said.

Pharma hesitant

The proposed law would not actually create a "right," since drug companies and research labs would remain the only ones to decide whether or not to share their treatments.

The difference is that the FDA would no longer have authority to approve or deny, but would simply be notified, particularly in case of serious adverse events.

"Pence, Trump talk about the right to try, but we already have the right to try," said Caplan.

"What they're creating is a right to beg, but we already have that. People do ask companies all the time."

The National Organization for Rare Disorders (NORD) said they are opposed because "the legislation still creates an unnecessary, less-safe alternative pathway that will not increase access to investigational therapies for our patients," said Paul Melmeyer, NORD director of federal policy.

Not to mention the fact that "a drug can make you die more miserably and can certainly make you die quicker," added Caplan.

Opponents and backers of the idea do agree on one thing—not enough is being done by companies that are in a position to help.

Small laboratories, which drive therapeutic innovation, often don't have the means to manage individual requests for drugs in addition to their work in clinical trials.

When it comes to big pharma, they often fear that the death of a patient, even a very sick one, would lead to bad headlines, or a crackdown on the drug by health authorities.

The proposed law aims to encourage companies to participate by giving them legal immunity and stipulating that the FDA could not block any medication from the market if a patient outside a clinical trial dies trying it.

"We're trying to give companies a level of clarity and certainty that they can help someone under the Right to Try program, and the FDA is not going to shut their trial down if that person dies," said Starlee Coleman, senior policy advisor at the Goldwater Institute, a libertarian think-tank that has driven the "right to try" idea.

She pointed out that the French system is more advanced than the US when it comes to exceptional uses of medications that are not yet on the market.

According to the latest report from France's National Agency for Medication Safety (ANSM), nearly 20,000 patients took advantage of individual authorization in 2016 in France, more than 20 times that in the United States.

Explore further: 'Right-to-try' laws: A patient's best last chance or false hope?

Related Stories

'Right-to-try' laws: A patient's best last chance or false hope?

April 6, 2017
(HealthDay)—The Trump administration may have failed in its initial effort to repeal the Affordable Care Act, but some activists hope White House support will prove valuable in changing another piece of federal health care ...

Dying patients want easier access to experimental drugs. Experts say that's bad medicine

March 29, 2017
Former firefighter Mike DeBartoli is a man desperate to rescue himself. He suffers from amyotrophic lateral sclerosis, the degenerative nerve disorder better known as Lou Gehrig's disease, which usually kills within five ...

J&J seeks bioethics advice on compassionate use of drugs

May 7, 2015
Dying patients sometimes seek emergency access to experimental medicines, desperate for a last-chance treatment even if there's little proof it could help. Now drug giant Johnson & Johnson is taking an unusual step, turning ...

'Right to try' laws make safety and efficacy secondary to speedy access

May 19, 2016
State "right to try" laws can give terminally ill patients early access to experimental drugs and medical devices, but they arguably make safety and efficacy secondary to speedy access, according to a new report by science ...

FDA eases paperwork to help some patients get experimental drugs

June 10, 2016
The Food and Drug Administration removed an obstacle from of its "compassionate use" policy this month, eliminating some paperwork that physicians must do to obtain experimental drugs for some patients with immediately life-threatening ...

US states move to expand experimental drug use (Update)

May 17, 2014
Nick Auden didn't live to see the legislation, but the case of the Colorado melanoma patient who died while seeking access to an experimental drug helped inspire a first-of-its kind law.

Recommended for you

New study finds concurrent use of prescription drugs and dietary supplements could pose health risks

September 25, 2018
A new University of Hertfordshire study found that using certain over-the-counter herbal medicines and dietary supplements alongside prescription drugs could pose serious health risks, especially amongst older adults.

Drug overdose epidemic has been growing exponentially for decades

September 20, 2018
Death rates from drug overdoses in the U.S. have been on an exponential growth curve that began at least 15 years before the mid-1990s surge in opioid prescribing, suggesting that overdose death rates may continue along this ...

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

Probiotic use may reduce antibiotic prescriptions, researchers say

September 14, 2018
Use of probiotics is linked to reduced need for antibiotic treatment in infants and children, according to a review of studies that probed the benefits of probiotics, say researchers in the U.S., England and the Netherlands.

Recalled blood pressure drugs not linked to increased short term cancer risk

September 12, 2018
Products containing the withdrawn blood pressure drug valsartan are not associated with a markedly increased short term risk of cancer, finds an expedited analysis published by The BMJ today.

Sugar pills relieve pain for chronic pain patients

September 12, 2018
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology. And the pills will reduce their pain as effectively as any powerful drug on the market, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.